Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Tax-Fleeing Takeover Mania Surges Forward

Health-care companies are increasingly looking to flee the U.S. for lower corporate tax rates and to access cash trapped overseas. While all deals will pale in comparison with Pfizer's failed pursuit of AstraZeneca, that would-be deal has seemingly ignited an inversion deal mania.

Our newest potential coupling is big pharma AbbVie (NYSE: ABBV  ) and Ireland-based Shire  (NASDAQ: SHPG  ) . It's not an obvious fit for AbbVie beyond the immediate tax benefits, but Shire is an ADHD and burgeoning orphan-drug powerhouse growing at a faster rate than its peers.

In this episode of Market Check-Up, The Motley Fool's health-care-focused investing show, analysts David Williamson and Michael Douglass discuss this new proposed inversion deal, how Shire might respond, and what it means for investors. 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. To that end, there is a product in development that will change how we treat a common chronic illness and also potentially revolutionize the entire health industry. Analysts are already licking their chops at the sales potential. To outsmart Wall Street and realize multibagger returns, you need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. Click here now.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3011798, ~/Articles/ArticleHandler.aspx, 9/3/2015 3:20:46 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated Moments ago Sponsored by:
DOW 16,412.38 61.00 0.37%
S&P 500 1,951.80 2.94 0.15%
NASD 4,754.57 4.59 0.10%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/3/2015 3:04 PM
ABBV $61.97 Up +0.99 +1.62%
AbbVie Inc. CAPS Rating: ****
AGN.DL $0.00 Down +0.00 +0.00%
Allergan, Inc. CAPS Rating: ****
AZN $32.24 Up +0.56 +1.77%
AstraZeneca plc (A… CAPS Rating: ****
NPSP.DL $0.00 Down +0.00 +0.00%
NPS Pharmaceutical… CAPS Rating: ****
PFE $32.02 Up +0.05 +0.16%
Pfizer CAPS Rating: ****
SHPG $223.50 Down -2.90 -1.28%
Shire plc (ADR) CAPS Rating: ****
VRX $229.50 Down -2.68 -1.15%
Valeant Pharmaceut… CAPS Rating: ***